Philippe Tinmouth, the Chief Business and Strategy Officer of Pardes Biosciences, Inc. (the Company) provided notice of his resignation from the Company effective November 30, 2022. In connection with Mr. Tinmouth's resignation, the Company and Mr. Tinmouth entered into a transition and separation agreement and general release of claims (the Separation Agreement). The Separation Agreement provides that upon Mr. Tinmouth's separation from the Company and contingent upon Mr. Tinmouth executing a supplemental general release of claims within the specified consideration period and such release becoming effective, Mr. Tinmouth will receive an amount equal to one month of his base salary payable on December 30, 2022 and will be entitled to up to one month of COBRA premiums paid by the Company.

The Separation Agreement contains a reaffirmation of Mr. Tinmouth's confidentiality and restrictive covenant obligations to the Company and a general release of claims.